Movement Alert｜Twist Bioscience Corp Falls 6.31% in Regular Trading, Prior Rating Initiations and Eli Lilly TuneLab Collaboration Continue to Be Digested

Market Focus10-30

On October 30, Twist Bioscience Corp fell 6.31% in Regular Trading, trading at $160.46 per share, with turnover of $51.59 million.

The move appeared tied to continued digestion of earlier catalysts rather than a fresh incremental trigger. Public information showed recent analyst coverage remained cautious, with Jefferies initiating at Hold with a $150 price target and UBS at Neutral with a $144 price target, while the company had also disclosed a collaboration to provide antibody characterization data services to Eli Lilly's TuneLab AI/ML drug discovery platform, focused on antibody drug discovery.

Recent market updates indicated those developments had previously lifted attention, but the latest disclosed information did not point to a stronger new catalyst, suggesting intensified capital rotation and valuation debate ahead of the company’s next earnings release on November 12.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment